Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Unecritinib in Advanced Cancer
NCT03019276Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2017
- Primary completion
- Dec 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of unecritinib in solid tumor (advanced stage), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose at 48 weeks, Dose-Limiting Toxicity at 4 weeks and 5 more. Status: unknown.
02
Drugs
unecritinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03019276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03019276.